Tg Therapeutics (TGTX) Cash & Current Investments (2011 - 2026)

Tg Therapeutics' Cash & Current Investments history runs 16 years deep, the most recent figure standing at $75.1 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 72.82% year-over-year to $75.1 million in Q1 2026; TTM through Mar 2026 was $75.1 million, a 72.82% decrease from a year earlier, with the FY2025 full-year figure at $64.1 million, down 51.21% from the prior year.
• Cash & Current Investments advanced to $75.1 million in Q1 2026 per TGTX's latest filing, from $64.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $341.0 million in Q3 2024 and bottomed at $64.1 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $209.8 million (2024), against an average of $194.1 million.
• Across the five-year window, Cash & Current Investments soared 50.16% in 2024 and slumped 72.82% in 2026, its largest moves.
• Year by year, Cash & Current Investments stood at $161.7 million in 2022, then jumped by 34.53% to $217.5 million in 2023, then slumped by 39.55% to $131.5 million in 2024, then sank by 51.21% to $64.1 million in 2025, then gained by 17.05% to $75.1 million in 2026.
• Per Business Quant, the three latest TGTX Cash & Current Investments figures stand at $75.1 million (Q1 2026), $64.1 million (Q4 2025), and $235.8 million (Q3 2025).